Logo West Pharmaceutical Services

West Pharmaceutical Services (WST) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
West Pharmaceutical Services · Health Care · ref. ETF XLV · 50 calls · price $371.82
🏆JPI 2026 portfoliosSee tracking →
What the company does: West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

📈 West Pharmaceutical Services (WST) stock price

$371.82+42.4% over range
Oct 14, 25low $230.95 · high $376.76Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 9 analysts
📊 JPI status : West Pharmaceutical Services has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 WST price target & analyst consensus — price $372

The price target · all analysts combined (9 targets)
Highest target · 1 firm of 9$447+20.2%
Median target · of 9 targets$413.5+11.2%
Lowest target · 1 firm of 9$360-3.2%
Current price$371.82
Where these 9 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 889% $390 ↔ $447
Below 111% $360
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $400 (+7.6 %), call made on September 23, 2026, maturing on September 23, 2027 (21 d ago).

The 5 reliable analysts $415+12 %
The 4 other firms $405+8.9 %
How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $415 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 9 ratings (last 6 months)
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about West Pharmaceutical Services? The JPI assistant answers using our backtest data.

💰 West Pharmaceutical Services dividend: yield, history & growth › open the full page

0.24%annual yield
🏆 Aristocrat — 33 yrs of consecutive dividend increases
That's ~$0.87 per share per year.

📈 West Pharmaceutical Services fundamentals: valuation, margins & growth › open the full page

P/E 47.6Net margin 17.0 %Revenue growth +13.8 %Somewhat expensive

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 20 %
2023
Rev +2%Profit +1%
2024
Rev −2%Profit −17%
2025
Rev +6%Profit +0%

🔎 Detailed analyses

✅ Historical analyst reliability on WST

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Wells Fargo ↗ 100% +19.6% 3
Evercore ISI Group ↗ 100% +15.2% 2
Keybanc ↗ 55% +6.4% 11
UBS ↗ 50% +5.4% 2
Jefferies ↗ 50% +2.0% 2
Stephens & Co. ↗ 33% -2.7% 3
B of A Securities ↗ 29% -22.8% 7

📊 What $1,000 invested in West Pharmaceutical Services would be worth › open the full page

In short — $1,000 invested in West Pharmaceutical Services 10 years ago would be worth $5,788 today, i.e. +19%/yr on average. Best year: 2020 (+86%), worst: 2024 (-35%). Price performance, excluding dividends.

If I'd invested $1,000 in West Pharmaceutical Services

InvestmentWorth todayGain
1 years ago$1,545+55%
3 years ago$1,132+13%
5 years ago$1,279+28%
→ See West Pharmaceutical Services's full return history + gain calculator

Return by year (West Pharmaceutical Services)

YearReturn$1,000 invested at year start
2026 (YTD)+41%$1,411 (+41%)
2025+9%$1,545 (+55%)
2024-35%$1,002 (+0%)
→ See West Pharmaceutical Services's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on West Pharmaceutical Services

Loading news…

📋 All analyst calls on WST

TD Cowen ↗
Oct 13, 26
▲ Buy · 🎯$420
Today : $371.82 — upside +13%
🎯 on WST : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Oct 13, 27
Barclays ↗
Oct 7, 26
▲ Overweight · 🎯$440
Price at call : $363.27 — upside +21%
Today : $371.82 — upside +18%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 7, 27
Morgan Stanley ↗
Sep 22, 26
▲ Overweight · 🎯$400
Price at call : $371.09 — upside +8%
Today : $371.82 — upside +8%
🎯 on WST : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Sep 22, 27
UBS ↗
Sep 9, 26
▲ Buy · 🎯$415
Price at call : $344.25 — upside +21%
Today : $371.82 — upside +12%
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Sep 9, 27
Citigroup ↗
Aug 3, 26
▲ Buy · 🎯$412
Price at call : $348.76 — upside +18%
Today : $371.82 — upside +11%
🎯 on WST : 0% (1 call matured) · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Aug 3, 27
▲ Outperform · 🎯$425
Price at call : $337 — upside +26%
Today : $371.82 — upside +14%
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Jul 27, 27
BNP Paribas
Jul 13, 26
▲ Outperform · 🎯$447
Price at call : $357.65 — upside +25%
Today : $371.82 — upside +20%
🎯 on WST : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jul 13, 27
■ Equal-Weight neutral · not a buy · 🎯$365
Price at call : $353.71 — gap to target +3%
Today : $371.82 — gap to target -2%
🎯 on WST : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Jul 9, 27
See the other 42 calls, newest to oldest
▲ Outperform · 🎯$410
Price at call : $356.08 — upside +15%
Today : $371.82 — upside +10%
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Jul 6, 27
Keybanc ↗
Jul 2, 26
▲ Overweight · 🎯$390
Price at call : $365.74 — upside +7%
Today : $371.82 — upside +5%
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Jul 2, 27
Barclays ↗
Jun 9, 26
▲ Overweight · 🎯$400
Price at call : $334.66 — upside +20%
Today : $371.82 — upside +8%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jun 9, 27
▲ Overweight · 🎯$360
Price at call : $312.17 — upside +15%
Today : $371.82 — upside -3%
🎯 on WST : 33% (3 calls matureds) · 📊 on Health : 52.5% · +0.2% (99 calls)
in progress (365j)
matures : Jun 2, 27
Morgan Stanley ↗
May 29, 26
■ Equal-Weight neutral · not a buy · 🎯$325
Price at call : $316.3 — gap to target +3%
Today : $371.82 — gap to target -13%
🎯 on WST : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : May 29, 27
Barclays ↗
Apr 27, 26
■ Equal-Weight neutral · not a buy · 🎯$310
Price at call : $292.13 — gap to target +6%
Today : $371.82 — gap to target -17%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Apr 27, 27
Barclays ↗
Apr 14, 26
■ Equal-Weight neutral · not a buy · 🎯$275
Price at call : $266.5 — gap to target +3%
Today : $371.82 — gap to target -26%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Apr 14, 27
Barclays ↗
Feb 13, 26
■ Equal-Weight neutral · not a buy · 🎯$265
Price at call : $243.19 — gap to target +9%
Today : $371.82 — gap to target -29%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Feb 13, 27
▲ Outperform · 🎯$320
Price at call : $230.95 — upside +39%
Today : $371.82 — upside -14%
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Feb 3, 27
■ Equal-Weight neutral · not a buy · 🎯$285
Price at call : $284.31 — gap to target +0%
Today : $371.82 — gap to target -23%
🎯 on WST : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Dec 2, 26
TD Cowen ↗
Oct 29, 25
▲ Buy · 🎯$350
Price at call : $284.86 — upside +23%
Today : $371.82 — upside -6%
🎯 on WST : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Oct 29, 26
Barclays ↗
Oct 27, 25
■ Equal-Weight neutral · not a buy · 🎯$325
Price at call : $283.49 — gap to target +15%
Today : $371.82 — gap to target -13%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 27, 26
UBS ↗
Oct 24, 25
▲ Buy · 🎯$355
Price at call : $287.22 — upside +24%
Today : $371.82 — upside -5%
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Oct 24, 26
Keybanc ↗
Oct 24, 25
▲ Overweight · 🎯$350
Price at call : $297.47 — upside +18%
Today : $371.82 — upside -6%
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
in progress (365j)
matures : Oct 24, 26
▲ Outperform · 🎯$390
Price at call : $297.47 — upside +31%
Today : $371.82 — upside +5%
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Oct 23, 26
Barclays ↗
Oct 2, 25
■ Equal-Weight neutral · not a buy · 🎯$275
Price at call : $273.16 — gap to target +1%
Today : $371.82 — gap to target -26%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 2, 26
Rothschild & Co
Sep 15, 25
▲ Buy · 🎯$311
Price at call : $258.35 — upside +20%
Today : $371.82 — upside -16%
Expected +20% · Actual +40% · Reason (≥ +15%) : ✓ Yes
🎯 on WST : 100% (1 call matured) · 📊 unranked overall
+40.1%
stock +40% · XLV +23%
matured Sep 15, 26
UBS ↗
Jul 25, 25
▲ Buy · 🎯$320
Price at call : $257.76 — upside +24%
Today : $371.82 — upside -14%
Expected +24% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
+28.5%
stock +29% · XLV +21%
matured Jul 25, 26
▲ Outperform · 🎯$350
Price at call : $257.76 — upside +36%
Today : $371.82 — upside -6%
Expected +36% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
+28.5%
stock +29% · XLV +21%
matured Jul 25, 26
Barclays ↗
Jul 25, 25
■ Equal-Weight neutral · not a buy · 🎯$260
Price at call : $263.51 — gap to target -1%
Today : $371.82 — gap to target -30%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jul 25, 26
Barclays ↗
Jun 24, 25
■ Equal-Weight neutral · not a buy · 🎯$245
Price at call : $222.68 — gap to target +10%
Today : $371.82 — gap to target -34%
🎯 on WST : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jun 24, 26
▲ Outperform · 🎯$275
Price at call : $234.47 — upside +17%
Today : $371.82 — upside -26%
Expected +17% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on WST : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
+1.9%
stock +2% · XLV +0%
matured Mar 18, 26
Keybanc ↗
Feb 14, 25
▲ Overweight · 🎯$325
Price at call : $211 — upside +54%
Today : $371.82 — upside -13%
Expected +54% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
+15.3%
stock +15% · XLV +9%
matured Feb 14, 26
Citigroup ↗
Jan 8, 25
▲ Buy · 🎯$400
Price at call : $331.73 — upside +21%
Today : $371.82 — upside +8%
Expected +21% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on WST : 0% (1 call matured) · 📊 on Health : 53.1% · +2.4% (516 calls)
-16.9%
stock -17% · XLV +13%
matured Jan 8, 26
▲ Buy · 🎯$355
Price at call : $330.57 — upside +7%
Today : $371.82 — upside -5%
Expected +7% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on WST : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)
-17.8%
stock -18% · XLV +12%
matured Dec 13, 25
Wolfe Research ↗
Dec 13, 24
■ Peer Perform neutral · not a buy
🎯 on WST : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Dec 13, 25
UBS ↗
Dec 12, 24
▲ Buy · 🎯$390
Price at call : $330.05 — upside +18%
Today : $371.82 — upside +5%
Expected +18% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
-17.6%
stock -18% · XLV +11%
matured Dec 12, 25
UBS ↗
Feb 16, 24
■ Neutral neutral · not a buy · 🎯$375
Price at call : $350.18 — gap to target +7%
Today : $371.82 — gap to target +1%
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Feb 15, 25
Keybanc ↗
Feb 13, 24
▲ Overweight · 🎯$470
Price at call : $398.59 — upside +18%
Today : $371.82 — upside +26%
Expected +18% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-19.1%
stock -19% · XLV +2%
matured Feb 12, 25
Jefferies ↗
Feb 7, 24
▲ Buy · 🎯$536
Price at call : $413 — upside +30%
Today : $371.82 — upside +44%
Expected +30% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on WST : 0% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
-20.0%
stock -20% · XLV +2%
matured Feb 6, 25
Stephens & Co. ↗
Oct 27, 23
▲ Overweight · 🎯$390
Price at call : $319.86 — upside +22%
Today : $371.82 — upside +5%
Expected +22% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on WST : 33% (3 calls matureds) · 📊 on Health : 52.5% · +0.2% (99 calls)
-2.9%
stock -3% · XLV +20%
matured Oct 26, 24
Keybanc ↗
Aug 30, 23
▲ Overweight · 🎯$440
Price at call : $409.12 — upside +8%
Today : $371.82 — upside +18%
Expected +8% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-23.1%
stock -23% · XLV +16%
matured Aug 29, 24
Keybanc ↗
Aug 21, 23
▲ Overweight · 🎯$415
Price at call : $392.68 — upside +6%
Today : $371.82 — upside +12%
Expected +6% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-23.8%
stock -24% · XLV +16%
matured Aug 20, 24
Keybanc ↗
Jul 28, 23
▲ Overweight · 🎯$385
Price at call : $365.46 — upside +5%
Today : $371.82 — upside +4%
Expected +5% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
-21.2%
stock -21% · XLV +11%
matured Jul 27, 24
Stephens & Co. ↗
Jul 17, 23
▲ Overweight · 🎯$420
Price at call : $384.59 — upside +9%
Today : $371.82 — upside +13%
Expected +9% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on WST : 33% (3 calls matureds) · 📊 on Health : 52.5% · +0.2% (99 calls)
-15.0%
stock -15% · XLV +14%
matured Jul 16, 24
▲ Buy · 🎯$405
Price at call : $362.04 — upside +12%
Today : $371.82 — upside +9%
Expected +12% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on WST : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)
-7.2%
stock -7% · XLV +10%
matured Jun 15, 24
Stephens & Co. ↗
Apr 11, 23
▲ Overweight · 🎯$400
Price at call : $354.81 — upside +13%
Today : $371.82 — upside +8%
Expected +13% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on WST : 33% (3 calls matureds) · 📊 on Health : 52.5% · +0.2% (99 calls)
+9.8%
stock +10% · XLV +6%
matured Apr 10, 24
Keybanc ↗
Feb 17, 23
▲ Overweight · 🎯$375
Price at call : $313.72 — upside +20%
Today : $371.82 — upside +1%
Expected +20% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
+11.6%
stock +12% · XLV +10%
matured Feb 17, 24
Deutsche Bank ↗
Dec 14, 22
■ Hold neutral · not a buy · 🎯$250
Price at call : $243.58 — gap to target +3%
Today : $371.82 — gap to target -33%
🎯 on WST : no call matured yet · 📊 on Health : 53.1% · +4.5% (292 calls)
in progress (365j)
matures : Dec 14, 23
Keybanc ↗
Dec 2, 22
▲ Overweight · 🎯$315
Price at call : $244.35 — upside +29%
Today : $371.82 — upside -15%
Expected +29% · Actual +44% · Reason (≥ +15%) : ✓ Yes
🎯 on WST : 43% (7 calls matureds) · 📊 on Health : 43.4% · -1.8% (145 calls)
+43.6%
stock +44% · XLV -6%
matured Dec 2, 23
UBS ↗
Nov 30, 22
■ Neutral neutral · not a buy · 🎯$250
Price at call : $234.66 — gap to target +7%
Today : $371.82 — gap to target -33%
🎯 on WST : 50% (2 calls matureds) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Nov 30, 23
■ Neutral neutral · not a buy · 🎯$250
Price at call : $225.51 — gap to target +11%
Today : $371.82 — gap to target -33%
🎯 on WST : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)
in progress (365j)
matures : Oct 28, 23

Frequently asked questions

Should I buy West Pharmaceutical Services stock?

This isn't buy advice. For West Pharmaceutical Services, the analyst consensus is "Buy", with an average price target of $414 (+11% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (3 calls tracked on West Pharmaceutical Services). We show the numbers — you decide.

Is it too late to buy West Pharmaceutical Services? How high can it go?

The most bullish analyst target on West Pharmaceutical Services is $447 (+20% above today's price); the average is $414. That's the upside they see. Check how reliable those analysts have actually been on West Pharmaceutical Services on our site before trusting it.

Is West Pharmaceutical Services still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 7 analysts have a real record on West Pharmaceutical Services, the best hitting 100% over 3 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in West Pharmaceutical Services? The case for and against

The arguments for and against, one by one, from the numbers: why invest in WST (and why hesitate).

What has West Pharmaceutical Services's past performance been?

Historical returns and a "how much if I had invested" calculator: WST performance & returns.

Does West Pharmaceutical Services pay a dividend?

Yield, consistency and growth history of the dividend: WST's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)